Loading clinical trials...

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | Clinical Trials | Clareo Health

TERMINATEDPhase 2NCT00515086

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

This study will define the safety and efficacy of Everolimus (RAD001) administered daily in patients with glioblastoma multiforme (GBM)

Lead sponsor: Novartis Pharmaceuticals•8 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1/2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more

RECRUITINGPhase 1

Sonodynamic Therapy in Patients With Recurrent GBM

NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more

RECRUITINGNA

Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]

NCT06466031 · Glioblastoma Multiforme

RECRUITINGPhase 1/2

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

NCT03596086 · Glioblastoma Multiforme, Astrocytoma, Grade III

RECRUITING

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512 · Glioblastoma Multiforme

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 22, 2011Terms

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment41

Start dateAug 2007

Last updatedSep 22, 2011

Condition

Glioblastoma Multiforme

Locations shown

UCLA

Los Angeles, California

Northwestern University

Chicago, Illinois

Massachusetts General Hospital

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 22, 2011Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions